Degron Therapeutics vs Gossamer Bio

Degron Therapeutics vs Gossamer Bio, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Degron Therapeutics is on 62/100 and Gossamer Bio on 54/100.

Degron Therapeutics logo
Degron TherapeuticsClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Try Degron Therapeutics
Gossamer Bio logo
Gossamer BioA biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
Try Gossamer Bio

Where each one leads

Degron Therapeutics

  • our overall score: 62/100 against 54/100

Gossamer Bio

  • agent readiness: 47/100 against 27/100
  • domain rating: 49/100 against 25/100
  • headcount: 154 against 24
  • funding raised: $150M against $40.0M
  • LinkedIn following: 14,489 against 1,380

At a glance

MeasureDegron TherapeuticsGossamer Bio
What it isClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
CategoryBiotechnology, Pharmaceuticals, Drug Discovery, HealthcareBiotechnology, Pharmaceuticals, Healthcare, Biotech
Sells toBusiness modelB2BB2B
OfferingPlatformServices
Founded20202017
HeadquartersSan Diego, USASan Diego, USA
StatusActiveActive

Size, funding and growth

MeasureDegron TherapeuticsGossamer Bio
Employees24154
Total funding$40.0M$150M
Latest roundSeries A ExtensionSeries B
Valuation$1.1B$1.1B
LinkedIn followers1,38014,489

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureDegron TherapeuticsGossamer Bio
StartupHub scoreOur 0-100 rating62/10054/100
TractionNot published60/100
Team24/100Not published
Search visibility57/10030/100
QualityNot published68/100
Agent readinessHow well an AI agent can read and act on the siteF (27/100)D (47/100)
Domain ratingLink authority, 0-10025/10049/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureDegron TherapeuticsGossamer Bio
HostingSelf ManagedNot detected
CDNNot detectedCloudflare
CMSNot detectedWordPress
FrameworksNot detectedJquery
AnalyticsNot detectedGoogle Tag Manager

Degron Therapeutics vs Gossamer Bio: common questions

Which is better, Degron Therapeutics or Gossamer Bio?

On our 0-100 score Degron Therapeutics rates higher (62/100 against 54/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.

How do Degron Therapeutics and Gossamer Bio compare on the numbers?

Degron Therapeutics leads on our overall score (62/100 against 54/100). Gossamer Bio leads on agent readiness (47/100 against 27/100), domain rating (49/100 against 25/100), headcount (154 against 24), funding raised ($150M against $40.0M), LinkedIn following (14,489 against 1,380).

Read the full Degron Therapeutics review and pricing or the Gossamer Bio review and pricing. You can also browse other Degron Therapeutics alternatives we track.